Unveiling quality of clinical trial in China: from concern to confirmation

Huiyao Huang; Yiru Hou; Hong Fang; Ling Xu; Yue Yu; Huifang Zhang; Jing Zhang; Yu Tang; Gongtao Lan; Wenbao Zhang; Ning Li

doi:10.1002/cac2.12528

Cancer Communications ›› 2024, Vol. 44 ›› Issue (5) :576 -579. DOI: 10.1002/cac2.12528

NEWS AND VIEWS

Unveiling quality of clinical trial in China: from concern to confirmation

Author information +

History +

PDF

Cite this article

Download citation ▾

Huiyao Huang, Yiru Hou, Hong Fang, Ling Xu, Yue Yu, Huifang Zhang, Jing Zhang, Yu Tang, Gongtao Lan, Wenbao Zhang, Ning Li. Unveiling quality of clinical trial in China: from concern to confirmation. Cancer Communications, 2024, 44(5): 576-579 DOI:10.1002/cac2.12528

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li N, Huang HY, Wu DW, Yang ZM, Wang J, Wang JS, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019;20(11):e619-e626.

[2]	Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, et al. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol. 2022;23(11):e515-e520.

[3]	Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds. BMJ. 2016;355:i5396.

[4]	Cyranoski D. China cracks down on fake data in drug trials. Nature. 2017;545(7654):275.

[5]	Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y, et al. Pharmacovigilance in China: Evolution and future challenges. Br J Clin Pharmacol. 2023;89(2):510-522.

[6]	National Medical Products Administration. Website of ICH work office [2023 08-20]. Available from:

[7]	U.S Food and Drug Administration. Dashboards - Compliance Dashboards [2023 08-20]. Available from:

[8]	Ma Y, Wang Q, Duan Y, Shi Q, Zhang X, Yang K, et al. Promoting the quality and transparency of health research in China. J Clin Epidemiol. 2022;152:209-217.

[9]	Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365-4377.